RET gene abnormalities and thyroid disease: Who should be screened and when

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 5, Issue SUPPL.1, 2013, Pages 70-78

  Salehian, Behrouz ^a   Samoa, Raynald ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

RET gene; Screening; Thyroid cancer

Indexed keywords

ARGININE; CALCITONIN; CALCIUM; COLECALCIFEROL; CYSTEINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENVATINIB; METADRENALIN; MITOGEN ACTIVATED PROTEIN KINASE; NORMETADRENALIN; PENTAGASTRIN; PLACEBO; PROTEIN RET; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

AMNIOCENTESIS; CELL HYPERPLASIA; CELL PROLIFERATION; DEATH; DISEASE ASSOCIATION; ENDOCRINE TUMOR; GANGLIONEUROMA; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPARATHYROIDISM; IMMUNOCHEMISTRY; NODULAR HYPERPLASIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT LARYNGEAL NERVE PALSY; RET GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; THYROIDECTOMY;

EID: 84874519799     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/Jcrpe.870     Document Type: Review

References (54)

1. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-394.
2. Mulligan LM, Kwok BJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
3. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-1694.
4. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42:581-588.
5. Ceccherini I, Bocciardi R, Luo Y, Pasini B, Hofstra R, Takahashi M, Romeo G. Exon structure and flanking intronic sequences of the human RET proto-oncogene. Biochem Biophys Res Commun 1993;196:1288-1295.
6. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995;11:2039-2045.
7. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005;16:441-467.
8. Asai N, Iwashita T, Matsuyama M, Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995;15:1613-1619.
9. Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. The GDNF family ligands and receptors - implications for neural development. Curr Opin Neurobiol 2000;10:103-110.
10. Boikos SA, Stratakis CA. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment. Histol Histopathol 2008;23:109-116.
11. Manié S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 2001;17:580-589.
12. Brandi ML, Gagel R, Angeli A, Bilezikian J, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti, Tonelli, Wells SA Jr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
13. Landsvater RM, de Wit MJ, Zewald RA, Hofstra RMW, Buys CHM, van Amstel HK, Höppener JWM, Lips CJM. Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res 1996;56:4853-4855.
14. Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-1622.
15. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 2007;33:493-497. Epub 2006 Nov 27
16. Favia G, Iacobone M. Medullary thyroid carcinoma: state of the art. G Chir 2005;26:405-409.
17. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105-1113.
18. Guyetant S, Wion-Barbot N, Rousselet MC, Franc B, Bigorgne JC, Saint-Andre JP. C-cell hyperplasia associated with chronic Iymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum Pathol 1994;25:514-521.
19. Dotto J, Nose V. Familial thyroid carcinoma: a diagnostic algorithm. Adv Anat Pathol 2008;15: 332-349.
20. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009;8:23-28.
21. Kvols LK. Men 2A, 2B, and non-Men Familial Medullary Thyroid Carcinoma. Holland-Frei Cancer Medicine, 6th ed Kufe DW, Pollock RE, Weichselbaum RR, et al. Hamilton (ON): BC Decker, 2003.
22. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M. Early presentation of metastatic medullary thyroid carcinoma in multiple endocrine neoplasia, type IIA: Implication for therapy. J Pediatr 1996;129:459-464.
23. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148.
24. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley J, Goodfellow P, Wells SA Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
25. Eng C, Schuffenecker DCI, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJM, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue, Xue, Noll WW, Romei C, Pacini, Fink M, Niederle B, Zedenius Z, Nordenskjöld M, Komminoth, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996;276:1575-1579.
26. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001;86:1104-1109.
27. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 2011;74:241-247.
28. Lesueur, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah PD, Ponder BA. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006;66:1177-1180.
29. Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews™. Seattle (WA): University of Washington, Seattle; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/ NBK1116/
30. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel R, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
31. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist 2008;13:539-547.
32. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003;138:409-416.
33. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch, Raue F, Conte-Devolx B, Dralle H, European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
34. Grubbs EG, Waguespack SG, Rich TA, Xing Y, Ying AK, Evans DB, Lee JE, Perrier ND. Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A? Surgery 2010;148:1302-1310.
35. Machens A, Dralle H. title typecontributorBenefit-risk balance of reoperation for persistent medullary thyroid cancer/title. Ann Surg 2012 Dec 21. Epub ahead of print
36. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001;8:345-354.
37. DeLellis RA. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006;94:662-669.
38. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002;13:3-16.
39. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998;4:287-294.
40. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini, Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EOncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995;55:5617-5620.
41. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS, Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997;15:1455-1460.
42. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000;290:138-141.
43. Pierotti MA, Bongarzone I, Borrello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer 1996;16:1-14.
44. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA. The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene 1994;9:1661-1668.
45. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A, Santoro M. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and retderived oncoproteins. J Clin Endocrinol Metab 2000;85:3898-3907.
46. Salehian B, Liu Z. Genetic alterations in differentiated thyroid cancers. Endocr Metab Immune Disord Drug Targets 2009;9:257-268. Epub 2009 Sep 1
47. Cheung CC, Carydis B, Ezzat S, Bedart YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 2001;86:2187-2190.
48. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-4412.
49. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, Hofstra RM. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96:991-995. Epub 2011 Apr 6
50. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684. Epub 2009 Mar 2
51. Hoftijzer H, Heemstra KA, Morreau H, Stokkel M, Corssmit E, Gelderblom H, Weiers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-931. Epub 2009 Sep 22
52. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588-2595. Epub 2010 Apr 14
53. Sherman SI. Targeted therapies for thyroid tumors. Mod Pathol 2011;24:44-52.
54. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol. 2011 Aug 23;7:617-24.v